OncoOne has been awarded a basic program grant from the FFG for our pioneering work on developing various drug modalities aimed at targeting oxidized macrophage migration inhibitory factor (oxMIF), a novel and promising drug target for solid tumor cancer indications. This grant is designed to stimulate research and development within Austrian companies, focusing on projects that promise significant technological advancement, market relevance, and economic impact. It supports startups like OncoOne in enhancing their liquidity situation over the medium term, with benefits such as covering up to 70% of relevant project costs, reinforcing our commitment to innovation in oncology.